Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study
Background: Postmenopausal osteoporosis is a multifactorial disease. Genetic factors play an essential role in contributing to bone mineral density (BMD) variability, which ranges from 60 to 85%. Alendronate is used as the first line of pharmacological treatment for osteoporosis; however, some patie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/14/2/524 |
| _version_ | 1797620737142423552 |
|---|---|
| author | Alejandra Villagómez Vega Jorge Iván Gámez Nava Francisco Ruiz González Misael Pérez Romero Walter Ángel Trujillo Rangel Ismael Nuño Arana |
| author_facet | Alejandra Villagómez Vega Jorge Iván Gámez Nava Francisco Ruiz González Misael Pérez Romero Walter Ángel Trujillo Rangel Ismael Nuño Arana |
| author_sort | Alejandra Villagómez Vega |
| collection | DOAJ |
| description | Background: Postmenopausal osteoporosis is a multifactorial disease. Genetic factors play an essential role in contributing to bone mineral density (BMD) variability, which ranges from 60 to 85%. Alendronate is used as the first line of pharmacological treatment for osteoporosis; however, some patients do not respond adequately to therapy with alendronate. Aim: The aim of this work was to investigate the influence of combinations of potential risk alleles (genetic profiles) associated with response to anti-osteoporotic treatment in postmenopausal women with primary osteoporosis. Methods: A total of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year were observed. The bone mineral density (BMD; g/cm<sup>2</sup>) of the femoral neck and lumbar spine was measured. According to BMD change, patients were divided into two groups: responders and non-responders to alendronate therapy. Polymorphic variants in <i>CYP19</i>, <i>ESR1</i>, <i>IL-6</i>, <i>PTHR1</i>, <i>TGFβ</i>, <i>OPG</i> and <i>RANKL</i> genes were determined and profiles were generated from the combination of risk alleles. Results: A total of 56 subjects were responders to alendronate and 26 subjects were non-responders. Carriers of the G-C-G-C profile (constructed from rs700518, rs1800795, rs2073618 and rs3102735) were predisposed to response to alendronate treatment (<i>p</i> = 0.001). Conclusions: Our findings highlight the importance of the identified profiles for the pharmacogenetics of alendronate therapy in osteoporosis. |
| first_indexed | 2024-03-11T08:46:54Z |
| format | Article |
| id | doaj.art-6a692075077f47edaf95590822967308 |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-11T08:46:54Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-6a692075077f47edaf955908229673082023-11-16T20:44:09ZengMDPI AGGenes2073-44252023-02-0114252410.3390/genes14020524Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort StudyAlejandra Villagómez Vega0Jorge Iván Gámez Nava1Francisco Ruiz González2Misael Pérez Romero3Walter Ángel Trujillo Rangel4Ismael Nuño Arana5Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44280, MexicoDoctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44280, MexicoClínica de Osteoporosis del Antiguo Hospital Civil “Fray Antonio Alcalde”, División de Medicina Interna, Guadalajara 44280, MexicoClínica de Osteoporosis del Antiguo Hospital Civil “Fray Antonio Alcalde”, División de Medicina Interna, Guadalajara 44280, MexicoCentro de Investigación Multidisciplinario en Salud, Departamento de Ciencias Biomédicas, Centro Universitario de Tonalá, Universidad de Guadalajara, Guadalajara 45425, MexicoDoctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44280, MexicoBackground: Postmenopausal osteoporosis is a multifactorial disease. Genetic factors play an essential role in contributing to bone mineral density (BMD) variability, which ranges from 60 to 85%. Alendronate is used as the first line of pharmacological treatment for osteoporosis; however, some patients do not respond adequately to therapy with alendronate. Aim: The aim of this work was to investigate the influence of combinations of potential risk alleles (genetic profiles) associated with response to anti-osteoporotic treatment in postmenopausal women with primary osteoporosis. Methods: A total of 82 postmenopausal women with primary osteoporosis receiving alendronate (70 mg administered orally per week) for one year were observed. The bone mineral density (BMD; g/cm<sup>2</sup>) of the femoral neck and lumbar spine was measured. According to BMD change, patients were divided into two groups: responders and non-responders to alendronate therapy. Polymorphic variants in <i>CYP19</i>, <i>ESR1</i>, <i>IL-6</i>, <i>PTHR1</i>, <i>TGFβ</i>, <i>OPG</i> and <i>RANKL</i> genes were determined and profiles were generated from the combination of risk alleles. Results: A total of 56 subjects were responders to alendronate and 26 subjects were non-responders. Carriers of the G-C-G-C profile (constructed from rs700518, rs1800795, rs2073618 and rs3102735) were predisposed to response to alendronate treatment (<i>p</i> = 0.001). Conclusions: Our findings highlight the importance of the identified profiles for the pharmacogenetics of alendronate therapy in osteoporosis.https://www.mdpi.com/2073-4425/14/2/524osteoporosisalendronatebone mineral densitysingle nucleotide polymorphismosteogenic profilepersonalized therapy |
| spellingShingle | Alejandra Villagómez Vega Jorge Iván Gámez Nava Francisco Ruiz González Misael Pérez Romero Walter Ángel Trujillo Rangel Ismael Nuño Arana Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study Genes osteoporosis alendronate bone mineral density single nucleotide polymorphism osteogenic profile personalized therapy |
| title | Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study |
| title_full | Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study |
| title_fullStr | Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study |
| title_full_unstemmed | Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study |
| title_short | Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study |
| title_sort | influence of the osteogenomic profile in response to alendronate therapy in postmenopausal women with osteoporosis a retrospective cohort study |
| topic | osteoporosis alendronate bone mineral density single nucleotide polymorphism osteogenic profile personalized therapy |
| url | https://www.mdpi.com/2073-4425/14/2/524 |
| work_keys_str_mv | AT alejandravillagomezvega influenceoftheosteogenomicprofileinresponsetoalendronatetherapyinpostmenopausalwomenwithosteoporosisaretrospectivecohortstudy AT jorgeivangameznava influenceoftheosteogenomicprofileinresponsetoalendronatetherapyinpostmenopausalwomenwithosteoporosisaretrospectivecohortstudy AT franciscoruizgonzalez influenceoftheosteogenomicprofileinresponsetoalendronatetherapyinpostmenopausalwomenwithosteoporosisaretrospectivecohortstudy AT misaelperezromero influenceoftheosteogenomicprofileinresponsetoalendronatetherapyinpostmenopausalwomenwithosteoporosisaretrospectivecohortstudy AT walterangeltrujillorangel influenceoftheosteogenomicprofileinresponsetoalendronatetherapyinpostmenopausalwomenwithosteoporosisaretrospectivecohortstudy AT ismaelnunoarana influenceoftheosteogenomicprofileinresponsetoalendronatetherapyinpostmenopausalwomenwithosteoporosisaretrospectivecohortstudy |